Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study
Keywords: 
Venetoclax
Chronic lymphocytic leukaemia
Dose ramp-up
Tumour lysis syndrome
Issue Date: 
2023
Publisher: 
Wiley
ISSN: 
1365-2141
Note: 
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License
Citation: 
Figueroa, R. (Rocío); Rampotas, A. (Alexandros); Halperin, D. (Daniel); et al. "Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study". British Journal of Haematology. 202 (1), 2023, 48 - 53
Abstract
This retrospective, observational study evaluated patterns of inpatient versus outpatient tumour lysis syndrome (TLS) monitoring during venetoclax ramp-up in 170 patients with chronic lymphocytic leukaemia. The primary outcome was clinical/biochemical TLS. Two clinical and four biochemical TLS occurred (4.1%). Five of the six events occurred in high-risk patients, four occurred at 20 mg dose and three at the 6-h time-point. Inpatient versus outpatient TLS rates within the high-risk subgroup were 15% and 8%. Risk category was the only predictor of TLS events in multivariate analysis. Outpatient escalation did not associate with clinically meaningful TLS events, suggesting outpatient escalation has manageable associated TLS risks, including in high-risk cohorts. These observations require confirmation in larger studies.

Files in This Item:
Thumbnail
File
Br J Haematol - 2023 - Figueroa‐Mora - Venetoclax ramp‐up strategies for chronic lymphocytic leukaemia in the United.pdf
Description
Size
541.03 kB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.